BIOMARIN PHARMACEUTICAL ($BMRN) posted quarterly earnings results for Q2 2026 on Thursday, August 6th. The company reported earnings of $1.20 per share, beating estimates of $0.70 by $0.50. The company also reported revenue of $989,710,000, beating estimates of $945,445,864 by $44,264,136.
Stock price change since market close: +4.46%
You can see Quiver Quantitative's $BMRN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOMARIN PHARMACEUTICAL Insider Trading Activity
BIOMARIN PHARMACEUTICAL insiders have traded $BMRN stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BMRN stock by insiders over the last 6 months:
- GEORGE ERIC DAVIS (EVP, Chief Legal Officer) sold 26,061 shares for an estimated $1,599,102
- CHARLES GREG GUYER (EVP, Chief Technical Officer) sold 16,486 shares for an estimated $996,743
- GREGORY R FRIBERG (EVP, Chief R&D Officer) sold 6,326 shares for an estimated $381,937
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BIOMARIN PHARMACEUTICAL Hedge Fund Activity
We have seen 264 institutional investors add shares of BIOMARIN PHARMACEUTICAL stock to their portfolio, and 259 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 3,147,943 shares (+230.7%) to their portfolio in Q1 2026, for an estimated $177,827,300
- FMR LLC added 1,729,960 shares (+94.2%) to their portfolio in Q1 2026, for an estimated $97,725,440
- SQUAREPOINT OPS LLC removed 1,468,642 shares (-80.3%) from their portfolio in Q1 2026, for an estimated $82,963,586
- BALYASNY ASSET MANAGEMENT L.P. added 1,362,752 shares (+inf%) to their portfolio in Q1 2026, for an estimated $76,981,860
- DEEP TRACK CAPITAL, LP removed 1,150,000 shares (-50.0%) from their portfolio in Q1 2026, for an estimated $64,963,500
- ARGA INVESTMENT MANAGEMENT, LP added 1,039,409 shares (+inf%) to their portfolio in Q2 2026, for an estimated $59,474,982
- VIKING GLOBAL INVESTORS LP added 1,025,141 shares (+17.0%) to their portfolio in Q1 2026, for an estimated $57,910,215
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BIOMARIN PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 05/22/2026
To track analyst ratings and price targets for BIOMARIN PHARMACEUTICAL, check out Quiver Quantitative's $BMRN forecast page.
BIOMARIN PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $BMRN recently. We have seen 14 analysts offer price targets for $BMRN in the last 6 months, with a median target of $83.5.
Here are some recent targets:
- Luca Issi from RBC Capital set a target price of $62.0 on 07/07/2026
- Whitney Ijem from Canaccord Genuity set a target price of $111.0 on 05/22/2026
- Eric Joseph from Citigroup set a target price of $75.0 on 05/19/2026
- Jason Zemansky from B of A Securities set a target price of $80.0 on 05/19/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $50.0 on 05/18/2026
- Salveen Richter from Goldman Sachs set a target price of $69.0 on 05/11/2026
- Matthew Harrison from Morgan Stanley set a target price of $119.0 on 05/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
